Podcasts

Join Professors Iain McInnes, Laura Coates, and Peter Nash as they discuss the latest top research in PsA. The first paper we will discuss aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with either TOFA, BARI or UPA. The second paper then goes on to describe the methodology being undertaken in the ground-breaking Phase 3b APEX study, which seeks to further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

Join Prof Iain McInnes as he reviews two interesting papers. In the first of today’s papers, Jeffrey Curtis and colleagues aimed to evaluate malignancies and their associations with baseline risk factors and CV risk scores with tofacitinib vs TNFi in a CV risk-enriched RA population from the ORAL Surveillance study. In the second paper today, Peter Taylor and his team analyse data from the baricitinib clinical trial programme for rheumatoid arthritis, atopic dermatitis, and alopecia areata, to help further characterise adverse events of special interest for JAK inhibitors in ‘at-risk’ populations.

Dr. Charis Meng, a rheumatologist at the Hospital for Special Surgery and Assistant Professor at Weill Cornell Medical College in New York. In this edition, Dr Meng discusses her latest paper ‘Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis.’

Join Prof Iain McInnes as he reviews two interesting papers. In the first paper, Professor Maxime Dougados and colleagues shed some more light into the findings from the ORAL Surveillance trial, in comparison to those seen in the tofacitinib clinical development programme. And, in the second paper, Professor Kevin Winthrop and colleagues continue to report on safety by providing us with the latest findings from their review into opportunistic infections associated with JAK inhibitor treatment for RA.

Join Professors Atul Deodhar, Hideto Kameda, Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses new and emerging treatments for SpA. In particular it shines a light on treatments within axSpA. Following this, our second paper sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.

Join Prof Iain McInnes as he reviews two interesting papers. In the first paper the authors cover aspects from mean disease activity scores after tapering to radiographic outcomes and safety, to help ascertain whether it is possible to withdraw MTX while maintaining disease control. The second paper then goes on to also analyse MTX withdrawal data, but this time to evaluate the performance of disease activity metrics. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com